RxSight Statistics
Total Valuation
RxSight has a market cap or net worth of $190.36 million. The enterprise value is -$54.00 million.
| Market Cap | 190.36M |
| Enterprise Value | -54.00M |
Important Dates
The last earnings date was Tuesday, November 3, 2026, after market close.
| Earnings Date | Nov 3, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
RxSight has 41.93 million shares outstanding. The number of shares has increased by 1.90% in one year.
| Current Share Class | 41.93M |
| Shares Outstanding | 41.93M |
| Shares Change (YoY) | +1.90% |
| Shares Change (QoQ) | +0.52% |
| Owned by Insiders (%) | 5.65% |
| Owned by Institutions (%) | 83.79% |
| Float | 34.93M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.56 |
| Forward PS | 1.23 |
| PB Ratio | 0.75 |
| P/TBV Ratio | 0.75 |
| P/FCF Ratio | 10.21 |
| P/OCF Ratio | 8.04 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.20, with a Debt / Equity ratio of 0.04.
| Current Ratio | 4.20 |
| Quick Ratio | 3.62 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | 0.55 |
| Interest Coverage | -4,389.64 |
Financial Efficiency
Return on equity (ROE) is -20.10% and return on invested capital (ROIC) is -83.88%.
| Return on Equity (ROE) | -20.10% |
| Return on Assets (ROA) | -11.84% |
| Return on Invested Capital (ROIC) | -83.88% |
| Return on Capital Employed (ROCE) | -23.15% |
| Weighted Average Cost of Capital (WACC) | 10.25% |
| Revenue Per Employee | $264,269 |
| Profits Per Employee | -$115,744 |
| Employee Count | 461 |
| Asset Turnover | 0.38 |
| Inventory Turnover | 0.85 |
Taxes
In the past 12 months, RxSight has paid $127,000 in taxes.
| Income Tax | 127,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -45.56% in the last 52 weeks. The beta is 1.19, so RxSight's price volatility has been higher than the market average.
| Beta (5Y) | 1.19 |
| 52-Week Price Change | -45.56% |
| 50-Day Moving Average | 5.23 |
| 200-Day Moving Average | 6.24 |
| Relative Strength Index (RSI) | 41.17 |
| Average Volume (20 Days) | 839,595 |
Short Selling Information
The latest short interest is 4.12 million, so 9.82% of the outstanding shares have been sold short.
| Short Interest | 4.12M |
| Short Previous Month | 4.09M |
| Short % of Shares Out | 9.82% |
| Short % of Float | 11.79% |
| Short Ratio (days to cover) | 5.26 |
Income Statement
In the last 12 months, RxSight had revenue of $121.83 million and -$53.36 million in losses. Loss per share was -$1.29.
| Revenue | 121.83M |
| Gross Profit | 92.75M |
| Operating Income | -61.46M |
| Pretax Income | -53.23M |
| Net Income | -53.36M |
| EBITDA | -57.84M |
| EBIT | -61.46M |
| Loss Per Share | -$1.29 |
Balance Sheet
The company has $254.68 million in cash and $10.32 million in debt, with a net cash position of $244.36 million or $5.83 per share.
| Cash & Cash Equivalents | 254.68M |
| Total Debt | 10.32M |
| Net Cash | 244.36M |
| Net Cash Per Share | $5.83 |
| Equity (Book Value) | 254.91M |
| Book Value Per Share | 6.08 |
| Working Capital | 239.85M |
Cash Flow
In the last 12 months, operating cash flow was $23.67 million and capital expenditures -$5.03 million, giving a free cash flow of $18.65 million.
| Operating Cash Flow | 23.67M |
| Capital Expenditures | -5.03M |
| Depreciation & Amortization | 3.61M |
| Net Borrowing | -12,000 |
| Free Cash Flow | 18.65M |
| FCF Per Share | $0.44 |
Margins
Gross margin is 76.13%, with operating and profit margins of -50.44% and -43.80%.
| Gross Margin | 76.13% |
| Operating Margin | -50.44% |
| Pretax Margin | -43.69% |
| Profit Margin | -43.80% |
| EBITDA Margin | -47.48% |
| EBIT Margin | -50.44% |
| FCF Margin | 15.30% |
Dividends & Yields
RxSight does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -1.90% |
| Shareholder Yield | -1.90% |
| Earnings Yield | -28.37% |
| FCF Yield | 9.79% |
Analyst Forecast
The average price target for RxSight is $7.57, which is 66.72% higher than the current price. The consensus rating is "Hold".
| Price Target | $7.57 |
| Price Target Difference | 66.72% |
| Analyst Consensus | Hold |
| Analyst Count | 10 |
| Revenue Growth Forecast (3Y) | 4.44% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
RxSight has an Altman Z-Score of -0.1 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.1 |
| Piotroski F-Score | 3 |